Ifosfamide and Mesna in Testicular Cancer
Author Information
Author(s): C. Bokemeyer, H.-J. Schmoll, E. Ludwig, A. Harstrick, T. Dunn, J. Casper
Primary Institution: Hannover University Medical School
Hypothesis
Does mesna affect the anti-tumour activity of ifosfamide in testicular cancer treatment?
Conclusion
Mesna does not impair the anti-tumour activity of ifosfamide in testicular cancer models.
Supporting Evidence
- Ifosfamide showed significant anti-tumour activity as a single agent.
- Mesna did not reduce the anti-tumour activity of ifosfamide at various dosages.
- Using mesna was associated with lower systemic and urothelial toxicity.
- Both cell lines used in the study demonstrated similar responses to treatment.
Takeaway
Ifosfamide is a medicine that helps treat testicular cancer, and using another medicine called mesna doesn't make it less effective.
Methodology
The study used xenografts from two human testicular cancer cell lines in nude mice to evaluate the effects of ifosfamide and mesna.
Limitations
The number of mice used limits the interpretation of results without larger statistical analysis.
Participant Demographics
Male athymic NMRI mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website